We would like to congratulate the authors for the first randomized phase 2 study comparing the effects of conventional transarterial chemoembolization (cTACE) and Y90 radioembolization (Y90) in patients with hepatocellular carcinoma (HCC).1 This study demonstrated that the primary endpoint, time to progression (TTP), was significantly longer for Y90 compared with cTACE, and no difference was observed in either tumor response rate or overall survival. We would like to highlight some points that might have biased the results.